Normal
• Positive EBITDA $576K and NPAT $66K• Revenue up 30.5% vs PCP• Biopolymer sales up 129% vs PCP• Gross profit margin 18.2% vs 14.2% PCP• Strong balance sheet: $14.3m cash with no debt
• Positive EBITDA $576K and NPAT $66K
• Revenue up 30.5% vs PCP
• Biopolymer sales up 129% vs PCP
• Gross profit margin 18.2% vs 14.2% PCP
• Strong balance sheet: $14.3m cash with no debt
Hello and welcome to Aussie Stock Forums!
To gain full access you must register. Registration is free and takes only a few seconds to complete.
Already a member? Log in here.
